Zika Virus Testing Market is likely to grow from US$ 4.9 Million in 2023 to US$ 6.8 Million by 2033

According to FMI, the market for testing for the Zika virus will likely increase from US$ 4.9 million in 2023 to US$ 6.8 million by 2033. The market is anticipated to experience a CAGR of 3.4% over the course of this forecast period. The rising incidence of Zika virus infection is a major factor driving the rising demand for Zika virus testing over the projection period.

The global zika virus testing market experienced a moderate incline, experiencing a CAGR of just above 2% between 2017 and 2020, being valued at a little over US$ 4 billion, as per ESOMAR-certified firm Future Market Insights (FMI) latest report on the landscape. Growth was majorly underpinned by the introduction of numerous point-of-care powerful testing approaches to facilitate timely detection of the virus.

According to FMI’s analysis, clinicians have been exhibiting a high preference towards enzyme linked immunosorbent assay (ELISA) tests. Compared to other immunoassay methods, ELISA tests are more accurate, are considered highly sensitive, specific and compare favorably with other methods used to detect substances in the body, such as radioimmune assay (RIA) tests.

To remain ‘ahead’ of your competitors, request for a sample

Prominent players are experiencing immense growth opportunities across tropical regions, attributed to the high concentration rate of the zika virus across such regions as the Caribbean, Central America, Africa and the Asian sub-continent. Players such as EUROIMMUN have emerged at the forefront, being the first diagnostics company to provide a testing approach to detect the zika virus. Its product lines include the Anti-Zika Virus ELISA (IgA or IgG or IgM or IgAM) fully automatable test and the IIFT Arbovirus Fever Mosaic 2 (IgG or IgM) test.

• EUROIMMUN US Inc.
• Creative Diagnostics
• Quest Diagnostics
• Artron Laboratories Inc.
• RapiGEN Inc.
• GenBody Inc.
• JAJ International Inc.
• LumiQuick Diagnostics Inc.
• Biocan Diagnostics Inc.
• NECTAR LIFESCIENCES LTD.
• Luminex Corporation
• ARUP Laboratories
• Abbott Molecular Inc.
• Hologic
• Vela Diagnostics

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-2913

Key Takeaways from FMI’s Zika Virus Testing Market Study

By test type, ELISA-based zika virus testing surpassed US$ 4 billion until 2020

By end-user, private commercial laboratories to remain primary point of contact for availing zika virus testing

Multiple regulatory approvals for various testing approaches by the FDA to bolster US zika virus testing market growth

Brazil to attract major zika virus testing providers amid increasing governmental initiatives to contain its spread

Growing focus on pregnant women’s health to accelerate testing volumes in Puerto Rico

UK to experience limited uptake amid the non-notifiable nature of the disease due to limited outbreaks

“Rising government initiatives to address possible suspected infection cases are providing a wide platform for the introduction of advanced zika virus testing approaches, providing key players a chance to expand their footprints across key geographies,” says the FMI analyst.

Competitive Landscape

Prominent zika virus testing manufacturers are reliant on offering advanced testing approaches in order to yield quicker results so as to facilitate timely treatment. Besides, key research laboratories and organizations also emphasize on expanding their testing capabilities by virtue of strategic acquisition and collaboration agreements.

In 2017, the US FDA issued an Emergency Use Authorization (EUA) to authorize the RealStar® Zika Virus RT-PCR Kit for the in vitro qualitative detection of Zika virus with specified instruments. This test is offered by Altona Diagnostics GmbH, and tests presence of the virus in human serum, EDTA plasma and/or urine.

Similarly, ARUP Laboratories offers both serology and RT-PCR tests for detecting the zika virus. The former is called the Zika Virus IgM Antibody Capture (MAC) based on the ELISA technique. In the latter case, the test is conducted by collecting patients’ blood or urine samples.

Key Segments Covered

Test Type

• Rapid IgG/IgM Test
• ELISA Test

End-User

• Hospitals & Clinics
• Private Commercial Laboratories
• Government/Publicly Funded Programs

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-2913

Region

• North America & Europe (US, UK, Germany, Spain, France, Italy and Rest of Europe)
• Latin America (Brazil, Mexico, Colombia  and Rest of LATAM)
• Central America (Costa Rica, Nicaragua, Guatemala and Rest of Central America)
• Caribbean (Puerto Rico and Rest of the Caribbean)
• South East Asia (Thailand, Singapore, Vietnam and Rest of South East Asia)
• Rest of the World (North Africa and South Africa)

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 8-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs